On November 18, 2018, local time in Belarus, the
Weichai Maz project, which was highly concerned by the heads of state of China and Belarus, began to enter the trial production stage at the Zhongbai “Jushi†industrial park, and a groundbreaking ceremony was held on the spot. Chinese Ambassador to Belarus Cui Qiming and Belarusian Minister of Industry Wu Qiuping jointly unveiled the company for Maz Weichai Co., Ltd.
Tan Xuguang, Chairman of Shandong Heavy Industry Weichai Group and Kazlikinic, General Manager of Maz Group, pressed the start button Tan Xuguang, chairman of Shandong Heavy Industry Weichai Group, and Katerinic, general manager of Maz Group, pressed the start button and the production line began trial operation.
Tan Xuguang accompanied the guests to visit the engine assembly, test run, complete production line
Tan Xuguang accompanied the guests to visit the engine assembly, commissioning, and complete production lines. The Maz Weichai plant has introduced the Weichai WOS operation management system, and introduced automated and intelligent manufacturing equipment and information systems. It mainly produces Euro 5 and Euro 6 engines for trucks, buses, construction machinery and agricultural equipment.
Tan Xuguang said that the project lasted for 7 months and created a miracle of project construction. We express our heartfelt gratitude to China National Engineering International and China Fifteen Metallurgical Construction Co., Ltd. for supporting the Weichai Maz project.
Reading volume:
Source: Weichai information Author: Yue Feng
Influenza Vaccine
Influenza Vaccine, Live, Nasal, Freeze-dried Exclusively authorized by the WHO in China WHO
Influenza Vaccine, Live, Nasal, Freeze-dried is a cooperative project with the WHO, which has been included in Global Action Plan for Influenza Vaccines (GAP)[1]. Hundreds of millions of doses have been used in the world, and Changchun BCHT Biotechnology Co. has the exclusive right of production and
operation in China.
Intranasal spray administration, no injection and no pain
The vaccine is inoculated by nasal spray, equipped with nasal spray device, and only needs to spray once a year in two nostrils to prevent influenza.
Mucosal immunity + Cellular immunity + Humoral immunity
After influenza virus attacks human body, it widely exists in nasal cavity, respiratory tract and other mucosal parts, as well as in body fluids and cells.
Vaccination of Influenza Vaccine, Live, Nasal, Freeze-dried can quickly stimulate the triple immune response of human body, and carry out defense
against viruses in different parts:
·Intranasal administration can produce mucosal immunity (IgA antibody), which forms the first immune defense line in the nasal cavity.
·Produce humoral immunity (IgG antibody) to remove influenza virus from body fluids.
·Produce cellular immunity (T cells) to remove influenza virus from cells
3+N More extensive protection
The production strains are recommended and supplied by the WHO every year.
The vaccine can not only effectively resist the vaccine strain, but also produce cross immunity to other subtypes of influenza virus.
Produced with SPF embryonated eggs
The chick embryos for vaccine production comes from SPF (specific pathogen free) chicken flocks, so the risk of exogenous pathogenic microorganism
pollution is excluded.
Free of inactivator, split agent and preservative
High protection and fast antibody production
This is the first influenza vaccine in China that has been evaluated by the protection effect of etiology in clinical stage. The protective effect of phase III
clinical trial is consistent with the literature[2]
.
First, the immune barrier was formed in the nasal mucosa after LAIV vaccination. It has been reported that the antibody of nasal mucosa can be
produced in 3 days[3], which greatly shortens the time for vaccine to produce
protective effect.
Influenza Vaccine,Influenza Vaccine Development,Influenza Vaccine Strains,Flu Vaccine
Changchun BCHT Biotechnology Co. , https://www.ccbcht.net